BFCH Announces Acquisition of ERApeutics, LLC to Expand in Cognitive Health Sector

BitFrontier Capital Holdings, Inc. (OTC: BFCH), under its operating name EVERMIND Holdings, Inc., has taken a decisive step towards strengthening its position in the cognitive health and wellness industry by entering into a binding Letter of Intent (LOI) to acquire ERApeutics, LLC. The acquisition, valued at $4,000,000, involves the issuance of 400,000,000 restricted common shares at $0.01 per share, showcasing BFCH's dedication to broadening its impact in this burgeoning sector.

The EVERMIND™ beverage platform, a physician-formulated, plant-based protein shake, is at the heart of this acquisition. Designed to support brain health with immediate and long-term benefits, EVERMIND™ stands out for its shelf stability, scientific validation, and market readiness. The deal encompasses six proprietary nootropic and adaptogenic formulations, alongside an R&D pipeline, academic research, trademarks, and a fully integrated e-commerce platform accessible at https://thinkevermind.com.

Dr. Jordan Balencic, CEO of BFCH, highlighted the strategic importance of EVERMIND™, drawing parallels to the transformative impact Celsius has had in the metabolism sector. This acquisition not only enhances BFCH's balance sheet with intellectual property-backed assets but also aligns with the company's broader strategy for an OTCQB uplisting. This strategic move comes on the heels of BFCH's successful elimination of over $2 million in toxic convertible debt, significantly reducing its total liabilities to under $94,000.

The functional beverage market is experiencing rapid growth, with industry giants like Keurig Dr Pepper and Coca-Cola making notable investments, underscoring the sector's vast potential. EVERMIND™ positions BFCH to tap into this lucrative market with its innovative, brain-focused product line. The transaction is anticipated to conclude within 60 to 90 days, subject to due diligence and final documentation. Following the acquisition, EVERMIND™ will function as a wholly owned subsidiary of EVERMIND Labs, with possibilities for future spin-offs. For further insights into the acquisition and BFCH's strategic trajectory, interested parties can explore the pitch at https://evermindholdings.com/evermind-beverage/. This acquisition marks a pivotal shift for BFCH from a legacy entity to a dynamic, growth-focused platform in the wellness and performance domains.